Amneal Pharmaceuticals
Profile managed by Bizz IdDescription
Products
15 productsBiosimilar to Orencia. Immunology. In development; expected approval 2028–2030.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Alymsys (bevacizumab-maly). Biosimilar referencing Avastin.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Cimzia. Immunology. In development; expected approval 2028–2030.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Boncresa. Biosimilar to Prolia. Osteoporosis. Vial. Launch undisclosed.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Oziltus. Biosimilar to XGEVA. Bone cancer. Vial. Launch undisclosed.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Trulicity. Diabetes. In development; expected approval 2028–2030.
Under development
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Dupixent. Respiratory. In development; expected approval 2030+.
Under development
Finished product (FDF)
Verified on 2026-10-21
Brand: Releuko (filgrastim-ayow). Biosimilar referencing Neupogen. Amneal's first US biosimilar (2022).
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Tremfya. Immunology. In development; expected approval 2030+.
Under development
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Opdivo. Oncology. In development; expected approval 2028–2030.
Under development
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to XOLAIR. Immunology/Allergy. Prefilled syringe. Not yet approved; estimated approval date.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Brand: Fylnetra (pegfilgrastim-pbbk). Biosimilar referencing Neulasta. Launched in the US in 2023.
Filing submitted
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Keytruda. Oncology. In development; expected approval 2028–2030.
Under development
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Skyrizi. Immunology. In development; expected approval 2030+.
Under development
Finished product (FDF)
Verified on 2026-10-21
Biosimilar to Nplate. Hematology. In development; expected approval 2028–2030.
Under development
Finished product (FDF)
Verified on 2026-10-21